Drug Trial Radar · NCT07059377
Semaglutide for Smoking Cessation in Patients With Diabetes
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 13, 2026
Primary completion
Dec 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Ottawa Heart Institute Research CorporationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.
Conditions
- Diabetes Mellitus, Type 2
- Nicotine Addiction
- Tobacco Dependence
Interventions
SemaglutideDrug
Starting dose will be 0.25mg once a week for 4 weeks, then titrated up to 0.5mg once a week. For those requiring additional blood sugar control, the dose may be titrated up to the maximum dose of 2mg once a week. All participants will use this medication for up to 26 weeks
Nicotine replacementDrug
Nicotine patch plus short-acting NRT gum or lozenge
Primary outcomes
What the sponsor says the trial is designed to measure.
- Project successTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Ottawa Heart Institute
Ottawa, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.